STAQUIS

This brand name is authorized in Austria, Estonia, Hong Kong SAR China, Israel, Lithuania, Poland, South Africa.

Active ingredients

The drug STAQUIS contains one active pharmaceutical ingredient (API):

1	Crisaborole UNII Q2R47HGR7P - CRISABOROLE
	Crisaborole is an anti-inflammatory benzoxaborole phosphodiesterase-4 (PDE4) inhibitor that suppresses secretion of certain cytokines, such as tumour necrosis factor-α (TNF-α), interleukins (IL-2, IL-4, IL-5), and interferon gamma (IFNγ), and improves skin barrier function as measured by transepidermal water loss (TEWL). It is used for treatment of mild to moderate atopic dermatitis in adults and paediatric patients.
	Read more about Crisaborole

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STAQUIS Ointment	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AH06		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1815566, 1815577, 1815588, 1815599
HK	Department of Health Drug Office	66644
IL	מִשְׂרַד הַבְּרִיאוּת	8540
LT	Valstybinė vaistų kontrolės tarnyba	1089893, 1089894, 1089895, 1089896
PL	Rejestru Produktów Leczniczych	100434037
ZA	Health Products Regulatory Authority	55/13.12/0287